SCHEMBL21704232

SCHEMBL21704232

Cc1cc(C(F)F)c2c(N)c(C)sc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.40
IKBKB O14920 7/20 0.40
ALDH1A1 P00352 5/20 0.40
HPGD P15428 4/20 0.40
CHUK O15111 2/20 0.40
PRKACA P17612 2/20 0.40
LIMK1 P53667 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 2/20 0.40
PRKACG P22612 1/20 0.40
PRKACB P22694 1/20 0.40
BTK Q06187 1/20 0.40
TSHR P16473 1/20 0.39
CHRM4 P08173 3/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 2/20 0.38
ATM Q13315 2/20 0.38
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20731019 0.87 KDM4E (0.43) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL22957552 0.80 KDM4E (0.53) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL18537675 0.78 KDM4E (0.61) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL22957550 0.75 KDM4E (0.72) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL23938092 0.74 KDM4E (0.39) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL19000276 0.74 ALDH1A1 (0.52) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL18537726 0.71 IKBKB (0.68) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL18537594 0.69 CDK8 (0.67) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL4656813 0.65 IKBKB (0.68) KDM4EIKBKBALDH1A1HPGDCHUK
SCHEMBL12600349 0.65 KDM4E (0.40) KDM4EIKBKBALDH1A1HPGDCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KDM4E 403/4885IKBKB 232/4885ALDH1A1 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.